FY2028 EPS Estimates for Nuvectis Pharma Reduced by Analyst

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Roth Capital cut their FY2028 earnings per share (EPS) estimates for Nuvectis Pharma in a research note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $3.23 per share for the year, down from their previous estimate of $3.61. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s FY2029 earnings at $4.24 EPS.

Separately, HC Wainwright lowered their target price on Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday.

Nuvectis Pharma Stock Performance

NVCT stock opened at $6.71 on Thursday. The stock’s 50 day simple moving average is $6.22 and its 200 day simple moving average is $6.41. The company has a market cap of $129.64 million, a P/E ratio of -5.78 and a beta of 0.22. Nuvectis Pharma has a fifty-two week low of $4.44 and a fifty-two week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Insider Buying and Selling at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri purchased 240,000 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was bought at an average price of $5.00 per share, for a total transaction of $1,200,000.00. Following the purchase, the insider now owns 2,884,121 shares of the company’s stock, valued at $14,420,605. The trade was a 9.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have acquired 261,500 shares of company stock valued at $1,300,825. Corporate insiders own 35.78% of the company’s stock.

Hedge Funds Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Iridian Asset Management LLC CT purchased a new stake in shares of Nuvectis Pharma in the third quarter worth about $348,000. Nations Financial Group Inc. IA ADV bought a new stake in shares of Nuvectis Pharma in the 3rd quarter valued at about $63,000. GSA Capital Partners LLP increased its stake in shares of Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after buying an additional 1,790 shares during the period. Geode Capital Management LLC grew its stake in shares of Nuvectis Pharma by 49.8% in the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after purchasing an additional 26,489 shares during the last quarter. Finally, Baldwin Wealth Partners LLC MA increased its stake in shares of Nuvectis Pharma by 104.4% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock valued at $1,926,000 after buying an additional 181,831 shares during the period. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.